ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 1171

Plasma Soluble ST2 Levels Are Independently Associated with Both Carotid Atherosclerosis and Compromised Cortical Volumetric Bone Mineral Density and Microstructure in Patients with Psoriatic Arthritis

Jiayun Shen1, Qing Shang1, Edmund Li1, Tracy Y. Zhu2, Ling Qin2 and Lai-Shan Tam1, 1Department of Medicine & Therapeutics, The Chinese University of Hong Kong, Hong Kong, China, 2Department of Orthopaedics & Traumatology, The Chinese University of Hong Kong, Hong Kong, China

Meeting: 2015 ACR/ARHP Annual Meeting

Date of first publication: September 29, 2015

Keywords: Atherosclerosis, Biomarkers, interleukins (IL), osteoporosis and psoriatic arthritis

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Date: Monday, November 9, 2015

Title: Cytokines, Mediators, Cell-cell Adhesion, Cell Trafficking and Angiogenesis Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose: Patients with PsA have both increased risk of subclinical atherosclerosis and lower cortical volumetric BMD (vBMD) compared with the general population, probably as a result of the dysregulated molecular pathways. We have reported that inflammation induced by the IL-33/ST2 axis was associated with carotid plaque progression in RA. Emerging data suggest that this axis may also be involved in bone homeostasis and osteoclastogenesis. In this study, we studied the association among IL-33/ST2 pathway, carotid plaque, and vBMD/bone microstructure in PsA patients.

Methods: 80 PsA patients (44 males; 53±10 years) without unstable cardiovascular diseases (CVD) or disorders that could affect bone metabolism were included. Carotid plaque was determined by ultrasound. vBMD and microstructure of the distal radius were measured using high-resolution peripheral quantitative CT (HR-pQCT). Plasma IL-33 and its decoy receptor soluble ST2 (sST2) levels were determined by ELISA.

Results: Plasma sST2 levels were significantly higher in 33 (41%) patients with carotid plaques (11.2±4.5 vs 7.7±3.7 ng/ml, p<0.001). The patients with plaques were also older (57±9 vs 50±10 years, p=0.002), had longer PsA duration (17±7 vs 12±7 years, p=0.006), and an increased prevalence of high CVD risk (Framingham 10-year CVD risk >10%: 64% vs 34%, p=0.013). The prevalence of hyperlipidemia was higher (36% vs 19%, p=0.085) and more patients were put on statins (27% vs 11%, p=0.046). After adjusting for these confounding factors, sST2 was an independent explanatory variable associated with the presence of carotid plaques (odds ratio: 1.3, 95% confidence interval [CI]: [1.2, 1.5]; p=0.003). Using linear regression, plasma sST2 level was negatively associated with cortical vBMD (coefficients: -5.4, 95%CI: [-8.6, -2.3], p=0.001), and positively associated with cortical porosity index (0.25, [0.12, 0.38], p<0.001) and cortical pore volume (3.0, [1.4, 4.6], p<0.001). The associations remained significant after adjusting for confounding factors1(Table 1). On the other hand, plasma IL-33 levels were not associated with the presence of carotid plaque or vBMD/microstructure.

Conclusion: Plasma sST2 levels are independently associated with both carotid plaque and compromised cortical vBMD/microstructure in PsA patients, indicating that IL-33/ST2 axis may contribute to both atherosclerosis and bone loss. The detailed mechanism should be further investigated.

1. Zhu TY, et al. Osteoporos Int. 2015;26:261-72.

Table 1. Univariate and multivariate linear regression analysis for the correlations among plasma sST2 level and HR-pQCT parameters

 

Unadjusted

Adjusted*

Coefficients (95%CI)

p

Coefficients (95%CI)

p

Ct. vBMD

-5.406 (-8.550, -2.263)

0.001

-2.918 (-6.111, 0.275)

0.073

Ct. TMD

-2.538 (-4.540, -0.536)

0.014

-0.723 (-2.808, 1.363)

0.492

Ct. thickness

0.009 (-0.007, 0.024)

0.257

Ct. Po

0.248 (0.116, 0.380)

<0.001

0.184 (0.042, 0.325)

0.012

Ct. PoV

2.973 (1.371, 4.575)

<0.001

2.247 (0.434, 4.060)

0.016

Ct. Po. Dm

-0.001 (-0.002, 0.001)

0.410

* Adjusted for age, gender, body mass index, hypertension, diabetes, ESR and CRP.

Ct., cortical; vBMD, volumetric BMD; TMD, tissue mineral density; Po, porosity index; PoV, pore volume; Po. Dm, pore diameter.


Disclosure: J. Shen, None; Q. Shang, None; E. Li, None; T. Y. Zhu, None; L. Qin, None; L. S. Tam, None.

To cite this abstract in AMA style:

Shen J, Shang Q, Li E, Zhu TY, Qin L, Tam LS. Plasma Soluble ST2 Levels Are Independently Associated with Both Carotid Atherosclerosis and Compromised Cortical Volumetric Bone Mineral Density and Microstructure in Patients with Psoriatic Arthritis [abstract]. Arthritis Rheumatol. 2015; 67 (suppl 10). https://acrabstracts.org/abstract/plasma-soluble-st2-levels-are-independently-associated-with-both-carotid-atherosclerosis-and-compromised-cortical-volumetric-bone-mineral-density-and-microstructure-in-patients-with-psoriatic-arthriti/. Accessed .
  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2015 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/plasma-soluble-st2-levels-are-independently-associated-with-both-carotid-atherosclerosis-and-compromised-cortical-volumetric-bone-mineral-density-and-microstructure-in-patients-with-psoriatic-arthriti/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology